An Evening with Dr. J. Leighton Read, co-founder of Affymax (sold to GSK)
Gibson, Dunn (building doorman will open door and escort to offices)
555 Mission Street
San Francisco
$25 members & non-members
Please join the Harvard Club of San Francisco in a fireside chat with Dr. J. Leighton Read, moderated by CapellaBio's CEO, Pek Lum.
Leighton is an American serial entrepreneur and venture investor with a long track record of building companies that have commercialized important medicines and life-science technologies. From 2000 – 2008 he wass a managing director of Alloy Ventures, an early-stage firm investing in life science and technology companies and he continues to look after his remaining portfolio companies as a Venture Partner. In 2015, he opened an office in the Bay Area for Brandon Capital Partners, Australia's leading life science venture fund.
Previously, he founded Affymax NV (with Alejandro Zaffaroni) where he served as Managing Director and President of the Pharma Division, sold to Glaxo SmithKline setting the stage for successful spin-outs, Affymetrix and Maxygen. He was the founding investor, Chairman and CEO of Aviron which developed FluMist™, the intranasal influenza vaccine acquired by MedImmune and was the founding CEO of Avidia, an Alloy portfolio sold to Amgen. Leighton has been a director of companies ranging from biotechnology, medical devices, materials science, energy and software. His current portfolio companies are Alexza, AnaptysBio, Cambrios, Genomatica, Siluria and SynergEyes.
Wednesday, March 16 at 6:30pm - 8:30pm
Gibson, Dunn (building doorman will open door and escort to offices)
555 Mission Street
San Francisco
Registration required by March 14
Event Organizer:
Eli Salomon
HLS '06